Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 3/2017

01-03-2017 | Original Article

Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients

Authors: Michalis Liontos, Eleni-Andriana Trigka, Penelope Korkolopoulou, Kimon Tzannis, Giorgos Lainakis, Konstantinos Koutsoukos, Efthymios Kostouros, Maria Lykka, Christos N. Papandreou, Vassilis Karavasilis, Christos Christodoulou, Athanasios Papatsoris, Andreas Skolarikos, Ioannis Varkarakis, Ioannis Adamakis, Christos Alamanis, Konstantinos Stravodimos, Dionysios Mitropoulos, Charalambos Deliveliotis, Constantinos A. Constantinidis, Angelica Saetta, Efstratios Patsouris, Meletios Α. Dimopoulos, Aristotelis Bamias

Published in: World Journal of Urology | Issue 3/2017

Login to get access

Abstract

Purpose

To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components.

Methods

The immunohistochemical expression of VEGF, p85α, p110γ, PTEN, p-Akt, p-mTOR, p-4E-BP1 and p-p70S6K was studied in 79 patients with mRCC who received first-line treatment with sunitinib. Expression was correlated with clinicopathological features and survival.

Results

VEGF was highly expressed (median H-Score 150), while positivity for the markers of the PI3K/Akt/mTOR pathway was: p85α 43/66 (65 %), p110γ41/60 (68 %), PTEN 32/64 (50 %), p-Akt57/63 (90 %), p-mTOR48/64 (75 %), p-4E-BP1 58/64 (90 %) and p-p70S6K 60/65 (92 %). No single immunohistochemical marker was found to have prognostic significance. Instead, the combination of increased p-mTOR and low VEGF expression was adversely correlated with overall survival (OS) (3.2 vs. 16.9 months, P = 0.001).

Conclusion

Immunohistochemistry for VEGF and p-mTOR proteins may discriminate patients refractory to first-line sunitinib with poor prognosis. Prospective validation of our findings is needed.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 112012
2.
Skolarikos A, Papatsoris AG, Alivizatos G, Deliveliotis C (2006) Molecular pathogenetics of renal cancer. Am J Nephrol 26:218–231CrossRefPubMed
3.
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124CrossRefPubMed
4.
Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731CrossRefPubMed
5.
Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939CrossRefPubMed
6.
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456CrossRefPubMed
7.
Escudier B, Porta C, Bono P et al (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 32(14):1412–1418CrossRefPubMed
8.
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456CrossRefPubMed
9.
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281CrossRefPubMed
10.
Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3):454–463CrossRefPubMed
11.
Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, Multicenter Study. J Clin Oncol 27(34):5794–5799CrossRefPubMed
12.
Heng DY, Signorovitch J, Swallow E et al (2014) Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies. PLoS ONE 9(12):e114264CrossRefPubMedPubMedCentral
13.
Heng DYC, Choueiri TK, Rini BI et al (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25(1):149–154CrossRefPubMedPubMedCentral
14.
Albiges L, Choueiri T, Escudier B et al (2015) A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 67(1):100–110CrossRefPubMed
15.
Maroto P, Rini B (2014) Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res 20(8):2060–2071CrossRefPubMed
16.
Pantuck AJ, Seligson DB, Klatte T et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 109(11):2257–2267CrossRefPubMed
17.
Bamias A, Karadimou A, Lampaki S et al (2010) Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer 10:45CrossRefPubMedPubMedCentral
18.
Trigka EA, Levidou G, Saetta AA et al (2013) A detailed immunohistochemical analysis of the PI3 K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep 30(2):623–636PubMed
19.
del Puerto-Nevado L, Rojo F, Zazo S et al (2014) Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. Br J Cancer 110(11):2700–2707CrossRefPubMedPubMedCentral
20.
Nicol D, Hii S-I, Walsh M et al (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157(4):1482–1486CrossRefPubMed
21.
Kluger HM, Siddiqui SF, Angeletti C et al (2008) Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 88(9):962–972CrossRefPubMed
22.
Paradis V, Lagha NB, Zeimoura L et al (2000) Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 436(4):351–356CrossRefPubMed
23.
Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Human Pathology 38(10):1489–1495
24.
Djordjevic G, Mozetic V, Mozetic DV et al (2007) Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 203(2):99–106CrossRefPubMed
25.
Klatte T, Seligson DB, LaRochelle J et al (2009) Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomark Prev 18(3):894–900CrossRef
26.
Dornbusch J, Zacharis A, Meinhardt M et al (2013) Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS ONE 8(9):e76386CrossRefPubMedPubMedCentral
27.
Minardi D, Lucarini G, Santoni M et al (2013) VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res 33(11):5017–5022PubMed
28.
Paule B, Bastien L, Deslandes E et al (2010) Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS ONE 5(5):e10715CrossRefPubMedPubMedCentral
29.
Peña C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16(19):4853–4863CrossRefPubMed
30.
Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312–3318CrossRefPubMed
31.
Garcia-Donas J, Leandro-García LJ, González del Alba A et al (2013) Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol 24(9):2409–2414CrossRefPubMed
32.
Motzer RJ, Hutson TE, Hudes GR et al (2014) Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol 74(4):739–750CrossRefPubMedPubMedCentral
33.
Davis ID, Long A, Yip S et al (2015) EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Ann Oncol 26(6):1118–1123CrossRefPubMed
34.
Sato Y, Yoshizato T, Shiraishi Y et al (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45(8):860–867CrossRefPubMed
35.
The Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43–49CrossRef
36.
Merseburger AS, Hennenlotter J, Kuehs U et al (2008) Activation of pi3k is associated with reduced survival in renal cell carcinoma. Urol Int 80(4):372–377CrossRefPubMed
37.
Hager M, Haufe H, Lusuardi L, Schmeller N, Kolbitsch C (2010) p-AKT overexpression in primary renal cell carcinomas and their metastases. Clin Exp Metastasis 27(8):611–617CrossRefPubMed
38.
Makhov PB, Golovine K, Kutikov A et al (2012) Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 11(7):1510–1517CrossRefPubMedPubMedCentral
39.
Heng DY, MacKenzie MJ, Vaishampayan UN et al (2012) Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 23(6):1549–1555CrossRefPubMed
40.
Metadata
Title
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients
Authors
Michalis Liontos
Eleni-Andriana Trigka
Penelope Korkolopoulou
Kimon Tzannis
Giorgos Lainakis
Konstantinos Koutsoukos
Efthymios Kostouros
Maria Lykka
Christos N. Papandreou
Vassilis Karavasilis
Christos Christodoulou
Athanasios Papatsoris
Andreas Skolarikos
Ioannis Varkarakis
Ioannis Adamakis
Christos Alamanis
Konstantinos Stravodimos
Dionysios Mitropoulos
Charalambos Deliveliotis
Constantinos A. Constantinidis
Angelica Saetta
Efstratios Patsouris
Meletios Α. Dimopoulos
Aristotelis Bamias
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 3/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1890-7

Other articles of this Issue 3/2017

World Journal of Urology 3/2017 Go to the issue

Letter to the Editor

Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?

Original Article

Postoperative patient comfort in suprapubic drainage versus transurethral catheterization following robot-assisted radical prostatectomy: a prospective randomized clinical trial

Original Article

Ligation-free technique for dorsal vascular complex control during laparoscopic radical prostatectomy: a single-center experience from China

Topic Paper

Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review

Original Article

Is overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry

Topic Paper

Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma